<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101139309</journal-id>
<journal-id journal-id-type="pubmed-jr-id">30413</journal-id>
<journal-id journal-id-type="nlm-ta">Lancet Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Lancet Neurol</journal-id>
<journal-title-group>
<journal-title>The Lancet. Neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1474-4422</issn>
<issn pub-type="epub">1474-4465</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26416172</article-id>
<article-id pub-id-type="pmc">4663979</article-id>
<article-id pub-id-type="doi">10.1016/S1474-4422(15)00199-4</article-id>
<article-id pub-id-type="manuscript">NIHMS726670</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Road Map for Precision Medicine in the Epilepsies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<collab>EpiPM Consortium</collab>
</contrib>
</contrib-group>
<author-notes>
<corresp id="FN1"><bold>Corresponding author:</bold> David B. Goldstein, Ph.D., Columbia University, New York, NY 10032, <email>dbgoldstein@columbia.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>7</day>
<month>10</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>9</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>14</volume>
<issue>12</issue>
<fpage>1219</fpage>
<lpage>1228</lpage>
<!--elocation-id from pubmed: 10.1016/S1474-4422(15)00199-4-->
<permissions>
<license license-type="open-access">
<license-p>This manuscript version is made available under the CC BY-NC-ND 4.0 license.</license-p>
</license>
</permissions>
<abstract>
<title>Summary</title>
<p id="P1">Technological advances have paved the way for accelerated genomic discovery and are bringing precision medicine clearly into view. Epilepsy research in particular is well-suited to serve as a model for the development and deployment of targeted therapeutics in precision medicine because of the rapidly expanding genetic knowledge base in epilepsy, the availability of good <italic>in vitro</italic> and <italic>in vivo</italic> model systems to efficiently study the biological consequences of genetic mutations, the ability to turn these models into effective drug screening platforms, and the establishment of collaborative research groups. Moving forward, it is critical that we strengthen these collaborations, particularly through integrated research platforms to provide robust analyses both for accurate personal genome analysis and gene and drug discovery. Similarly, the implementation of clinical trial networks will allow the expansion of patient sample populations with genetically defined epilepsy so that drug discovery can be translated into clinical practice.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>